Faster or Failed? ADC Developers Rethink How Drugs Get Built

Invenra and Xcellon Biologics link discovery and manufacturing early to speed next-generation ADCs toward the clinic

23 Oct 2025

The antibody drug conjugate market has no shortage of scientific ambition. What it often lacks is speed. A new collaboration between Invenra and Xcellon Biologics suggests the industry may be learning how to close that gap.

The US-based partnership is built around a simple idea: integrate discovery and manufacturing much earlier in drug development. For ADC programs, that shift could prove decisive as companies race to turn complex science into reliable cancer therapies.

ADCs pair tumor-seeking antibodies with highly potent drugs, aiming to kill cancer cells while sparing healthy tissue. Several have already reached patients, but the field is pushing into tougher territory. Many tumors are heterogeneous, meaning a single target is not enough. This has fueled interest in multispecific ADCs that can recognize more than one signal at a time.

Invenra has focused its platform on precisely that challenge. Its multispecific antibodies are designed to boost efficacy and reduce the chance that tumors evade treatment. The tradeoff is complexity. These molecules are harder to manufacture, harder to scale, and harder to reproduce consistently. Many promising candidates falter when they leave the lab.

That is where Xcellon Biologics enters the picture. The company specializes in bioconjugation and manufacturing for complex biologics, including ADCs. By aligning its capabilities with Invenra’s discovery platforms from the outset, the partners hope to uncover production and quality issues long before clinical trials begin.

Industry observers see this approach as part of a broader recalibration. Novel biology still matters, but development readiness is becoming just as critical. As ADC designs grow more sophisticated, early manufacturing insight can make the difference between momentum and delay.

The collaboration also reflects a wider shift in life sciences, with tighter links forming between discovery teams and development specialists. For patients, that could translate into faster access to innovative treatments. For developers, it may improve the odds that strong science survives the journey into the clinic.

Multispecific ADCs remain technically demanding and closely scrutinized by regulators. Still, by prioritizing readiness over late-stage fixes, Invenra and Xcellon are betting that the future of precision cancer care starts earlier than ever.